Kathleen Payne

Kathleen Payne serves as Chief Pharmacy Officer, providing strategic leadership over pharmaceutical procurement and clinical supply chain operations within her organization. In this capacity, she oversees the acquisition of analytical laboratory instruments and associated diagnostic technologies critical to pharmaceutical quality assurance, compounding validation, and pharmacovigilance programs. Her role bridges clinical pharmacy practice with federal acquisition policy, ensuring that procurement decisions align with regulatory compliance, patient safety standards, and scientific integrity. She typically manages complex, high-stakes acquisitions involving precision instrumentation, software-enabled lab systems, and certified reagent kits used in drug potency testing and contaminant analysis. While specific contractor relationships are not publicly enumerated, her procurement activity is concentrated within the analytical laboratory instrument manufacturing sector, indicating consistent engagement with vendors specializing in HPLC, GC-MS, spectrophotometric systems, and automated dispensing platforms. Her working relationships likely include both large-scale manufacturers with FDA-registered production facilities and niche suppliers offering validated, GMP-compliant equipment. These partnerships are characterized by rigorous technical evaluation, lifecycle cost analysis, and adherence to ASTM and USP standards. Ms. Payne’s contracting patterns reflect a strong preference for open competition, with 100% of acquisitions classified as “No Set-Aside,” indicating a focus on technical merit and performance capability over socioeconomic preferences. This approach prioritizes product efficacy, regulatory alignment, and operational reliability over socioeconomically targeted contracting mechanisms such as 8(a), HUBZone, or SDVOSB set-asides. Her primary NAICS focus—334516, Analytical Laboratory Instrument Manufacturing—underscores deep expertise in procuring advanced diagnostic and analytical equipment used in pharmaceutical testing. She specializes in acquiring instruments for residue analysis, purity verification, and stability testing, requiring deep familiarity with FDA 21 CFR Part 11, ISO 17025, and validation protocols. Her domain expertise ensures that all acquisitions meet the stringent demands of pharmaceutical quality control environments.